Becton, Dickinson and (NYSE:BDX) had its target price boosted by Argus to $235.00 in a research note issued to investors on Thursday, The Fly reports. The brokerage presently has a “buy” rating on the medical instruments supplier’s stock. Argus’ price objective suggests a potential upside of 7.34% from the stock’s current price. The analysts noted that the move was a valuation call.

Several other research firms have also weighed in on BDX. Wells Fargo & Company reaffirmed a “positive” rating and set a $235.00 price target (up previously from $225.00) on shares of Becton, Dickinson and in a research report on Tuesday, October 24th. They noted that the move was a valuation call. Piper Jaffray Companies reissued a “buy” rating and set a $213.00 target price on shares of Becton, Dickinson and in a report on Tuesday, September 12th. Morgan Stanley boosted their target price on Becton, Dickinson and from $205.00 to $245.00 and gave the stock an “equal weight” rating in a report on Friday, November 3rd. Royal Bank of Canada reissued a “sector perform” rating and set a $230.00 target price (up from $210.00) on shares of Becton, Dickinson and in a report on Friday, November 3rd. Finally, Stifel Nicolaus reissued a “buy” rating and set a $245.00 target price on shares of Becton, Dickinson and in a report on Friday, November 3rd. Four investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $218.36.

Becton, Dickinson and (BDX) opened at $218.94 on Thursday. The firm has a market capitalization of $49,910.00, a P/E ratio of 23.08, a price-to-earnings-growth ratio of 1.71 and a beta of 1.06. Becton, Dickinson and has a 1 year low of $161.50 and a 1 year high of $229.68. The company has a debt-to-equity ratio of 1.44, a quick ratio of 5.03 and a current ratio of 5.58.

Becton, Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.37 by $0.03. The firm had revenue of $3.17 billion for the quarter, compared to analyst estimates of $3.14 billion. Becton, Dickinson and had a return on equity of 20.56% and a net margin of 8.52%. The business’s quarterly revenue was down 2.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.12 EPS. sell-side analysts forecast that Becton, Dickinson and will post 10.63 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently modified their holdings of the business. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its holdings in Becton, Dickinson and by 55.8% in the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock valued at $131,000 after buying an additional 240 shares in the last quarter. Parkside Financial Bank & Trust grew its holdings in Becton, Dickinson and by 8.1% in the 2nd quarter. Parkside Financial Bank & Trust now owns 684 shares of the medical instruments supplier’s stock valued at $133,000 after buying an additional 51 shares in the last quarter. Harfst & Associates Inc. grew its holdings in Becton, Dickinson and by 46.4% in the 2nd quarter. Harfst & Associates Inc. now owns 697 shares of the medical instruments supplier’s stock valued at $135,000 after buying an additional 221 shares in the last quarter. Harvest Fund Management Co. Ltd grew its holdings in Becton, Dickinson and by 82.8% in the 2nd quarter. Harvest Fund Management Co. Ltd now owns 746 shares of the medical instruments supplier’s stock valued at $146,000 after buying an additional 338 shares in the last quarter. Finally, Acrospire Investment Management LLC grew its holdings in Becton, Dickinson and by 259.7% in the 2nd quarter. Acrospire Investment Management LLC now owns 831 shares of the medical instruments supplier’s stock valued at $162,000 after buying an additional 600 shares in the last quarter. 88.60% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Becton, Dickinson and (BDX) Price Target Increased to $235.00 by Analysts at Argus” was posted by American Banking News and is the property of of American Banking News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/14/becton-dickinson-and-bdx-price-target-increased-to-235-00-by-analysts-at-argus.html.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

The Fly

Analyst Recommendations for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.